CME event for healthcare professionals who manage dyslipidemia.
The correlation between elevations in total
cholesterol or low-density lipoprotein cholesterol (LDL-C) and
cardiovascular (CV) risk is well known by healthcare professionals.
However, knowledge and experience of lipid abnormalities outside of
LDL-C, such as pathologic levels of triglycerides, is very limited,
despite epidemiologic data that support the contribution of
hypertriglyceridemia to the development and progression of
Recent data has shown that pure eicosapentaenoic acid ethyl
ester (EPA) can reduce the risk for CV events. However, healthcare
practitioners (HCPs) in cardiology, primary care,
diabetology/endocrinology, and other settings have limited knowledge
about the biologic and antiatherosclerotic properties of EPA and the
potential for its combined use with statins to reduce residual CV risk
in patients with mixed dyslipidemia at high risk for CV events.
Join Drs Deepak Bhatt, Preston Mason, and William Weintraub as
they walk us through the current omega-3 landscape and how they can
improve CV outcomes in patients with dyslipidemia.